Should Ki-67 be included in the immunohistochemistry panel for an 11 mm low‑differentiated lung lesion staged T1aN0M0?

Ki-67 Should Be Included in the Immunohistochemistry Panel for This Low-Differentiated T1aN0M0 Lung Lesion

For an 11 mm low-differentiated lung lesion staged T1aN0M0, Ki-67 immunohistochemistry is strongly recommended as part of the diagnostic panel, particularly given the poor differentiation which suggests higher-grade pathology requiring proliferative assessment.

Rationale Based on Guidelines and Evidence

Primary Guideline Support

The 2013 American College of Chest Physicians guidelines 1 explicitly recommend Ki-67 for specific diagnostic scenarios in lung pathology. In small biopsy samples where distinguishing between small cell carcinoma and carcinoid tumors is challenging, a Ki-67 proliferation index offers more accurate distinction, with small cell carcinomas showing high indices of >50-70% versus carcinoids with low indices of 5-15% 1.

While your case is described as "low-differentiated," this terminology typically indicates poorly differentiated/high-grade pathology. The guidelines emphasize that for challenging cases, a diagnostic panel of immunohistochemical assays is recommended to increase diagnostic accuracy (Grade 1B) 1.

Clinical Context for Your Specific Case

For this 11 mm T1a lesion with low differentiation:

• Ki-67 provides critical prognostic information that correlates with tumor aggressiveness, particularly in early-stage disease 2, 3
• Low differentiation suggests higher proliferative activity, making Ki-67 assessment clinically meaningful for treatment planning
• In stage I lung adenocarcinoma, Ki-67 expression differs significantly by histological subtype, with solid-predominant (poorly differentiated) adenocarcinomas showing the highest Ki-67 expression 4

Prognostic Value in Early-Stage Disease

Recent evidence demonstrates that Ki-67 has important prognostic value in non-small cell lung cancer, though interpretation differs between adenocarcinoma and squamous cell carcinoma 2:

• In lung adenocarcinoma: high Ki-67 indicates poor prognosis
• In lung squamous carcinoma: paradoxically, low Ki-67 indicates worse prognosis due to higher metastatic capacity

For stage I adenocarcinoma specifically, high Ki-67 expression (>10-15%) is independently associated with worse differentiation and poor prognosis 4, 5.

Practical Implementation

The optimal Ki-67 assessment method uses:

• SP6 antibody (superior specificity over MIB1) 3
• Counting 2000 tumor cells from 10 random tiles (200 cells each) in invasive areas 3
• Cut-off value of 0.12 (12%) with alternative of 0.15 (15%) based on disease recurrence 3

For your 11 mm lesion, Ki-67 >10% would indicate high proliferative activity and potentially more aggressive behavior requiring closer surveillance or consideration of adjuvant therapy 5, 6.

Common Pitfalls to Avoid

• Do not rely solely on morphology for grading in small, early-stage lesions where Ki-67 can provide objective proliferative data
• Ensure adequate tissue sampling from invasive areas, not just lepidic components which may underestimate proliferative activity
• Request specific Ki-67 cut-off reporting (ideally using 10-15% thresholds) rather than just "positive/negative"
• Consider histologic subtype when interpreting Ki-67 results, as prognostic implications differ between adenocarcinoma and squamous cell carcinoma 2

In summary, Ki-67 immunohistochemistry should absolutely be part of your diagnostic panel for this low-differentiated T1aN0M0 lung lesion, as it provides objective proliferative assessment that complements morphologic grading and informs prognosis in early-stage disease.